Salarius Pharmaceuticals, Inc.
Salarius Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer therapies. They focus on correcting dysregulated gene expression in cancer cells using targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). Their lead protein inhibitor, seclidemstat (SP-2577), is in phase 1/2 trials for Ewing sarcoma and hematologic cancers. The company has received support from CPRIT and the National Pediatric Cancer Foundation. SP-3164 is expected to enter the clinic in the second half of 2023.
Official Registry
AI Quality Analysis
Trust Score Breakdown
Quick Links
Website Highlights
🌟 Similar Trusted Businesses
OKYO Pharma Ltd
OKYO Pharma Ltd. (NASDAQ:OKYO) is a biopharmaceutical company dedicated to developing an innovative treatment for neuropathic corneal pain and dry eye disease. Through its proprietary chemerin peptide, OK-101, the company aims to provide targeted therapy that alleviates pain, controls inflammation, and enhances ocular residence time for more effective, lasting relief.
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new treatments for gastrointestinal (GI) diseases, particularly acid-related disorders. They have licensed exclusive rights in the United States, Europe, and Canada to a potassium-competitive acid blocker (PCAB). Phathom is committed to transforming the treatment landscape and improving the lives of patients.
UroGen Pharma Ltd.
UroGen Pharma is a biopharmaceutical company focused on developing and commercializing innovative treatments for urologic cancers. They utilize RTGel® technology for sustained local delivery of medications to the urinary tract. Their key products include Jelmyto® and Zusduri™, representing advancements in uro-oncology treatment.